REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
- Thursday, December 8, 2022, 7:12
- PR Newswire
- Add a comment
RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIO’s clinical-stage pipeline of neurodegenerative disease programs. Expanded Cohort 2 enrollment is complete; eight patients have received RGX-111 in the trial Company intends to…
About the Author
admin has written 21043 stories on this site.